Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung

We present two cases of relapsed adenocarcinoma of the lung: a 50-year-old male and a 67-year-old male. Both patients had previously been treated with platinum-containing systemic chemotherapy. In both cases, significant clinical efficacy was demonstrated with combination chemotherapy consisting of...

Full description

Bibliographic Details
Published in:	Case Reports in Oncological Medicine
Main Authors:	Sae Wada, Nobukazu Fujimoto, Kenichi Gemba, Michiko Asano, Yasuko Fuchimoto, Katsuichiro Ono, Shinji Ozaki, Takumi Kishimoto
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Online Access:	http://dx.doi.org/10.1155/2012/821280

Similar Items

Bilateral Pleural Effusions as an Initial Presentation in Primary Sjögren’s Syndrome
by: Go Makimoto, et al.
Published: (2012-01-01)

Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report
by: Jun Nishimura, et al.
Published: (2017-07-01)

Lymphoproliferative disorder in pleural effusion in a subject with past asbestos exposure
by: Naofumi Hara, et al.
Published: (2015-01-01)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
by: Andrés Felipe Cardona, et al.
Published: (2016-01-01)

Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports
by: Tomonobu Koizumi, et al.
Published: (2025-01-01)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
by: Nicole F. Laslett, et al.
Published: (2018-07-01)

Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
by: Tian Y, et al.
Published: (2019-11-01)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
by: Schuette W, et al.
Published: (2017-11-01)

Sinus arrhythmia caused by pemetrexed with carboplatin combination: A case report
by: Xianghua Quan, et al.
Published: (2022-10-01)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
by: Takashi Kasai, et al.
Published: (2023-07-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
by: Nobukazu Fujimoto, et al.
Published: (2021-10-01)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
by: Ying He, et al.
Published: (2022-05-01)

Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma
by: Doğan Bayram, et al.
Published: (2025-10-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
by: Ryutaro Onaga, et al.
Published: (2023-06-01)

Acute pancreatitis caused by pemetrexed, carboplatin, and gemcitabine in a patient with lung cancer: A rare case report
by: Vishal Kulkarni, et al.
Published: (2019-01-01)

Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report
by: Keita Kawakado, et al.
Published: (2021-09-01)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
by: Jun Sugisaka, et al.
Published: (2023-11-01)

Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand
by: Kanyarat Katanyoo, et al.
Published: (2025-03-01)

Clinical Investigation of Benign Asbestos Pleural Effusion
by: Nobukazu Fujimoto, et al.
Published: (2015-01-01)

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report
by: Oranus Mohammadi, et al.
Published: (2021-01-01)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
by: Ping-Chih Hsu, et al.
Published: (2023-01-01)

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study
by: Wei Fang, et al.
Published: (2024-08-01)

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
by: Gota V, et al.
Published: (2014-06-01)

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
by: Leda Severi, et al.
Published: (2018-05-01)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
by: Shinya Sakata, et al.
Published: (2015-01-01)

Removal notice to “Sinus arrhythmia caused by pemetrexed with carboplatin combination: A case report” [Heliyon 8 (2022) e11006]
by: Xianghua Quan, et al.
Published: (2025-09-01)

Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet
by: Yanjuan Xiong, et al.
Published: (2017-05-01)

Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
by: Masafumi Yasunaga, et al.
Published: (2022-09-01)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)

CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib
by: Kazuhide Sato, et al.
Published: (2012-10-01)

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes
by: Jiun-Long Wang, et al.
Published: (2021-08-01)

A meta-analysis of Pemetrexed plus Platinum Chemotherapy versus Gemcitabine plus Platinum Chemotherapy for Advanced Non-small Cell Lung Cancer
by: Jin JIANG, et al.
Published: (2011-01-01)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
by: Hirotoshi Yasui, et al.
Published: (2014-08-01)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
by: Yiyang Qin, et al.
Published: (2017-12-01)

Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
by: V. La, et al.
Published: (2017-04-01)

Combinatorial treatment using bevacizumab/pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer
by: Deepika Radhakrishnan, et al.
Published: (2023-12-01)

Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study.
by: Hitoshi Kawazoe, et al.
Published: (2017-01-01)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
by: Kyaw Z. Thein, et al.
Published: (2022-02-01)